Previous Close | Open | Close* |
---|---|---|
0.23 | 0.24 | 0.245 |
Market Cap | Dividend Yield (Annualized) |
---|---|
AUD 71.598M | 0.00% |
Day Range |
---|
0.235L 0.245 H |
52 WEEK HIGH LOW |
---|
0.17L 0.63 H |
Last Trade | 0.245 |
---|---|
Change% | 6.5217 |
52 W H/L | 0.630/0.170 |
EBITDA | -9.629M |
NPAT After Abnormal Items | -9.347M |
Equity | 40.776M |
ROE% | -22.92% |
Total Liabilities | 7.077M |
Total Revenue | 14.432M |
Cash and Cash Equivalents | 26.796M |
Share price | 0.245 |
---|---|
Market Cap | 71.598M |
Price/Gross Cash Flow | -38.34 |
Dividend Yield Excluding Special | 0.00% |
Ending Shares | 288.222M |
52-Week Range | 0.630-0.170 |
Gross DPS (AUD) | 0 |
Gross Dividend Yield (Annualized) | 0.00% |
Earnings Yield | 3.040 |
Net Tangible Asset (NTA) | 0.14 |
P/E ratio | 32.895 |
Sector P/E | -- |
EPS | -3.54 |
EV/EBITDA | -- |
Net Profit Margin (%) | -- |
Gross Cash Flows Per Share | -0.02 |
Net Gearing | -64.86% |
Sales Per Share | 0.00 |
Book Value Per Share | 0.14 |
Noxopharm Limited is an ASX-listed clinical-stage drug development company focused on the potential treatment of a wide range of cancers. The company operates under the healthcare sector and aims to create unique anti-cancer drugs. It is backed by a solid pipeline of drug candidates including Veyonda®, the first oncology pipeline product. Housed in the non-oncology subsidiary, Nyrada Inc. are four pre-clinical R and D programs.
Suite 3 Level 4, 828 Pacific Highway, GORDON, NSW, AUSTRALIA, 2072
Ex-Date | Net Dividend | Frank Flag | Period End Date | Type | Payable |
---|
Event Type | Event Date | Event Year |
---|---|---|
Report (Interim) | 2023-02-20 | 2023 |
Report (Annual) | 2022-09-09 | 2022 |
Report (Annual) | 2022-08-25 | 2022 |
Report (Prelim) | 2022-08-25 | 2022 |